Roginolisib, a conformation-selective PI3Kδ inhibitor, delivered a first-in-human safety profile in an early cancer trial and generated median overall survival signals up to 20.8 months in metastatic uveal melanoma. The study also reported immune changes consistent with reduced tumour-induced immunosuppression. The early clinical readout focuses on tolerability in advanced cancers and secondary immune pharmacodynamics, aligning with ongoing efforts to pair PI3Kδ pathway modulation with immunotherapy-like mechanisms. The data reinforce PI3Kδ as an immune-relevant oncology target beyond classic kinase inhibition. While the report remains preliminary, the combination of survival-relevant outcomes and directionally supportive immune biomarker shifts makes roginolisib’s next-step trial design—dose escalation and expansion—especially important for patients with limited therapeutic options in uveal melanoma.